Bempegaldesleukin (NKTR-214)
18-214-12
Phase 1 mab terminated
Quick answer
Bempegaldesleukin (NKTR-214) for Metastatic Melanoma is a Phase 1 program (mab) at Nektar Therapeutics UK Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Nektar Therapeutics UK Limited
- Indication
- Metastatic Melanoma
- Phase
- Phase 1
- Modality
- mab
- Status
- terminated